Free, self-directed programs for continuing education credit.
Indications for Germline Testing after Genomic Tumor Testing
Learn how to interpret genomic test results to identify patients with hereditary risks.
Choosing the Best Genomic Tumor Test
Learn about the benefits and limitations of different genomic tumor test options for patients with cancer and how to determine the best test for each patient.
Exploring Cancer Biomarker Testing
Learn about benefits, limitations, and challenges of using large somatic cancer panels.
Interpreting Results from Somatic Cancer Panel
Practice interpreting cancer genetic testing results and reports within a patient-specific context.
Hereditary Cancer Syndromes: Are your Patients at Risk?
Develop skills and knowledge to identify those patients most appropriate for genetic testing, choosing the right test, and using the results to develop a management plan.
Genomic (Somatic) Tumor Testing
Multidisciplinary Expert Insights: Assessing Hereditary Cancer Risks for Genomic Tumor Testing. A multidisciplinary panel of clinical and laboratory experts discusses a case that highlights factors relevant for the interpretation of tumor results for hereditary risks.
How to Maximize the Genomic Tumor Board Experience. Suggests ways for you to make the most of the genomic tumor board experience.
Indications for Germline Testing in Cancer Patients. Provides a quick reference about the factors to consider when determining the appropriateness of germline testing.
Testing to Identify Genomic Variants Related to Cancer. Defines and compares benefits and limitations of type of testing: somatic, paired somatic/germline and concurrent somatic + germline.
Liquid Biopsy FAQ. Describes the benefits, risks and limitations of liquid biopsy.
Anatomy of Genomic Tumor Test Report. Annotated genomic tumor test report.
Nomenclature in Genomic Tumor Test Reports. Explains common nomenclature laboratories used to identify variants.
Comparing Somatic Cancer Panels. Provides information about how somatic tumor test offerings may differ among laboratories.
Assessing Genomic Variants for Targeted Therapy Options. Provides a framework for assessing the evidence supporting targeted treatment options.
PARP Inhibitors: Overview and Indications. Discusses FDA-approved indications for PARPi for maintenance therapy and cancer treatment as well as emerging uses under investigation.
Evaluating Immune Checkpoint Inhibition Biomarkers. Provides an overview of the benefits and limitations of commonly used immune checkpoint inhibition biomarkers.
Ordering and Interpreting PD-L1 Testing. Discusses which patients may benefit from PD-L1 testing and how to select and interpret tests for patients with different cancer types.
Communicating with Patients
Facilitating shared decision making about somatic tumor testing. Supports clinicians when communicating about the process, benefits, and limitations associated with somatic tumor testing.